Why the study?
Does the development of acute kidney injury increase in-hospital mortality in patients with acute myocardial infarction across different Killip classes?
Does the development of acute kidney injury increase in-hospital mortality in patients with acute myocardial infarction across different Killip classes?
Acute kidney injury is a strong predictor of in-hospital mortality in AMI patients presenting with Killip class 1 to 3, but its prognostic impact is attenuated in those presenting with cardiogenic shock (Killip 4).
Answers are grounded in this paper and cite their sources.
AKI signals higher in-hospital mortality risk in Killip 1-3 AMI; leaves open its independent role in cardiogenic shock.
BACKGROUND: Acute kidney injury (AKI) is associated with poor outcome after acute myocardial infarction (AMI), but whether hemodynamic status at presentation influences this prognostic significance is unknown. METHODS AND RESULTS: A total of 2,798 AMI patients admitted within 48 h after symptom onset and who underwent urgent coronary angiography were enrolled in the present study. AKI was defined as an increase in serum creatinine ≥0.3 mg/dL or ≥50% within 48 h during hospitalization. Patients were classified into 3 groups according to Killip class on admission: Killip 1, n=2,164; Killip 2-3, n=366; and Killip 4, n=268. AKI occurred more frequently with increasing Killip class (Killip 1, 2-3, and 4: 6.3%, 15.3%, and 31.3%, respectively; P<0.001). AKI was associated with increased in-hospital mortality, regardless of Killip class (non-AKI and AKI patients: 1.1% vs. 6.6% in Killip 1; 5.2% vs. 35.7% in Killip 2-3, and 28.8% vs. 45.2% in Killip 4, P<0.01 for all). On multivariate analysis, the adjusted OR of AKI for in-hospital mortality in Killip 1, Killip 2-3, and Killip 4 were 3.79 (95% CI: 1.54-9.33, P=0.004), 5.35 (95% CI: 2.67-10.7, P<0.001), and 1.48 (95% CI: 0.94-2.35, P=0.093), respectively. CONCLUSIONS: In AMI patients undergoing urgent coronary angiography, AKI was significantly associated with increased in-hospital mortality in Killip 1 as well as Killip 2-3 at presentation, but not in Killip 4.
No takes yet. Share an insight, caveat, or question.
Kuji et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: